Open: 5.13 Close: 5.24 Change: 0.11

Today's Summary

Neil Gallagher, M.D., Ph.D. and Stuart Duty were appointed to the Board of Directors. The new directors will provide strategic insights to advance Foghorns pipeline of selective therapies for challenging cancer targets. Foghorn Therapeutics focuses on developing medicines that correct abnormal gene expression. Foghorn Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. The company continues to advance its chromatin biology and degrader platform.